FY2027 EPS Estimates for IceCure Medical Cut by Analyst

IceCure Medical Ltd (NASDAQ:ICCM) – Investment analysts at Brookline Capital Management reduced their FY2027 earnings estimates for shares of IceCure Medical in a note issued to investors on Thursday, March 27th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings per share of $0.22 for the year, down from their previous forecast of $0.23. The consensus estimate for IceCure Medical’s current full-year earnings is ($0.28) per share. Brookline Capital Management also issued estimates for IceCure Medical’s FY2028 earnings at $0.32 EPS and FY2029 earnings at $0.42 EPS.

Separately, HC Wainwright restated a “buy” rating and issued a $2.50 price target on shares of IceCure Medical in a research note on Friday, March 28th.

IceCure Medical Stock Performance

NASDAQ ICCM opened at $1.24 on Monday. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. IceCure Medical has a twelve month low of $0.48 and a twelve month high of $1.66. The business has a 50-day moving average price of $1.31 and a 200-day moving average price of $1.00. The firm has a market cap of $68.82 million, a price-to-earnings ratio of -4.28 and a beta of 0.37.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The business had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.07 million. IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%.

Institutional Trading of IceCure Medical

A hedge fund recently raised its stake in IceCure Medical stock. XTX Topco Ltd grew its position in shares of IceCure Medical Ltd (NASDAQ:ICCM) by 123.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,866 shares of the company’s stock after purchasing an additional 32,555 shares during the period. XTX Topco Ltd owned approximately 0.11% of IceCure Medical worth $65,000 at the end of the most recent reporting period. Institutional investors own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.